Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Acrivon Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 48 | 55 | +7 |
| Shares | 15.2M | 23.5M | +8.22M (+53.9%) |
| Value | $109.0M | $136.1M | +$27.1M (+24.9%) |
New holders (12)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 659,724 | $3.83M | 0.15% |
| Jane Street Group, LLC | 30,714 | $178.1K | 0.00% |
| Goldman Sachs Group Inc | 24,384 | $141.4K | 0.00% |
| Squarepoint Ops LLC | 17,207 | $99.8K | 0.00% |
| Marex Group plc | 13,187 | $76.5K | 0.00% |
| Walleye Capital LLC | 12,721 | $73.8K | 0.00% |
| Occudo Quantitative Strategies LP | 12,552 | $72.8K | 0.01% |
| XTX Topco Ltd | 10,493 | $60.9K | 0.01% |
| Dimensional Fund Advisors LP | 10,066 | $58.4K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 6,508 | $37.7K | 0.00% |
| Corebridge Financial, Inc. | 6,355 | $36.9K | 0.00% |
| Federation des caisses Desjardins du Quebec | 400 | $2.32K | 0.00% |
Sold out (5)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Millennium Management LLC | 95,497 | $682.8K |
| Prelude Capital Management, LLC | 13,000 | $93.0K |
| Raymond James & Associates | 10,200 | $72.9K |
| American International Group, Inc. | 6,016 | $43.0K |
| Catalyst Funds Management Pty Ltd | 1,044 | $7.46K |